导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -19.65% | 4379/4773 |
| 近一周 | -4.08% | 4996/5465 |
| 近一月 | -3.32% | 2379/5421 |
| 近一季 | -5.92% | 2218/5231 |
| 近半年 | -18.68% | 4311/4920 |
| 近一年 | -24.86% | 4090/4394 |
| 近两年 | 3.39% | 2847/2954 |
| 近三年 | -30.47% | 2215/2253 |
| 成立以来 | -31.06% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-8.98% 4334/4961 |
-11.61% 4313/5312 |
- - |
- - |
| 2025 | 3.13% 3149/4813 |
-4.98% 3242/3635 |
-1.22% 3132/4076 |
19.92% 2079/4524 |
-8.38% 3909/4813 |
| 2024 | 0.19% 2083/3463 |
-7.96% 2209/2808 |
-10.26% 2433/3014 |
31.94% 105/3129 |
-8.06% 2827/3463 |
| 2023 | -24.05% 1965/2656 |
-4.95% 2124/2280 |
-8.29% 1980/2385 |
1.08% 322/2515 |
-13.80% 2469/2655 |
| 2022 | -8.76% 159/2207 |
7.94% 23/1919 |
-8.35% 1896/2016 |
-7.46% 128/2113 |
-0.33% 1595/2208 |
| 2021 | 5.03% 558/1822 |
-0.34% 357/1255 |
1.32% 1060/1330 |
3.22% 415/1466 |
0.77% 1061/1822 |
| 2020 | -6.69% 977/1250 |
-12.49% 890/1028 |
9.00% 804/1067 |
4.76% 943/1164 |
-6.62% 1144/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 华夏中证全指房地产ETF联接A VS. 长安沪深300非周期A(740101) |